| Literature DB >> 35893771 |
Abstract
Magnetic resonance imaging (MRI) and MR cholangiopancreatography (MRCP) have emerged as non-invasive diagnostic techniques for the diagnosis of pancreatic and pancreatic duct disorders in humans. The number of studies focused on MR and MRCP for pancreatic disease in small animals is very limited. MR has been described for the evaluation of insulinoma in dogs and to investigate pancreatitis in cats. The studies were based on a standard protocol with T2 weighted (w) fast recovery fast spin-echo (FRFSE) with and without fat suppression, T1w FSE pre-contrast and T1w FSE post-contrast with and without fat suppression. MRCP after secretin stimulation has been described in cats to assess the pancreatic ductal system, taking advantage of pulse sequences heavily T2w as rapid acquisition with rapid enhancement (RARE), fast-recovery fast spin-echo (FRFSE) sequences and single-shot fast spin-echo (SSFSE) sequences. In addition to the standard protocol, fast spoiled gradient recalled echo pulse sequences (fSPGR) and volume interpolated 3D gradient-echo T1w pulse sequences pre and post-contrast have also been used in cats, reaching the goal of assessing the biliary tree and the pancreatic duct with the same sequence and in multiple planes. Despite the small amount of data, the results show potential, and the most recent technical innovations, in particular, focused on diffusion MRI and fast acquisition, further support the need for continued evaluation of MRI as an effective instrument for the investigation of pancreatic disease.Entities:
Keywords: MRCP; MRI; endocrine; magnetic resonance imaging technique; pancreas; secretin
Year: 2022 PMID: 35893771 PMCID: PMC9332374 DOI: 10.3390/vetsci9080378
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
All the acronyms used in the review are listed in the first column, with their respective extended description in the second column.
| Acronym | Description |
|---|---|
| ADC | Apparent Diffusion Coefficient |
| CAIPIRINHA | Controlled Aliasing In Parallel Imaging Results In Higher Acceleration Factor |
| DWI | Diffusion Weighted Imaging |
| Efgr | Elliptical fast gradient echo |
| ERCP | Endoscopic Retrograde Cholangiopancreatography |
| FAME | Fast Acquisition with Multiphase Efgr |
| FISP | Fast Imaging with Steady State procession |
| FLASH | Fast Low Angle Shot |
| FOV | Field of View |
| FRFSE | Fast Recovery Fast Spin Echo |
| FSE | Fast Spin Echo |
| fSPGR | Fast Spoiled Gradient Recalled Echo Pulse Sequences |
| GRE | Gradient Echo |
| MPI | Maximum Intensity Projections |
| MRA | MR Angiography |
| MRCP | MR cholangiopancreatography |
| MRI | Magnetic Resonance Imaging |
| NEX | Number of Excitations |
| RARE | Rapid Acquisition with Rapid Enhancement |
| RF | Radiofrequency pulse |
| SSFSE | Single Shot Fast Spin Echo |
| TWIST | Time-resolved angiography With Interleaved Stochastic Trajectories |
| VIBE | Volume Interpolated Body Examination |
MRI and MRCP protocols, including technical details used in Walczak et al., 2019. “Dor” stays for dorsal, “tra” for transverse, “sag” for sagittal, and “obl” for oblique.
| Walczak et al., 2019, 1.5T GE | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-Contrast | Planes | TE ms | TR ms | Thickness mm | Gap mm | ||||
| Dor | Tra | Sag | Obl | 3D | |||||
| T1w FSE | ✓ | ✓ | 10.1–22.3 | 300–700 | 3.5–4.00 | 0.5 | |||
| T2w FRFSE | ✓ | ✓ | 95.5–97.3 | 2500–4600 | 3.5–4.00 | 0.5 | |||
| T2w FRFSE fat sat | ✓ | ✓ | 91.3–97.3 | 2776–5200 | 3.5–4.00 | 0.5 | |||
|
| |||||||||
| T1wFSE | ✓ | ✓ | 10.1–22.3 | 300–700 | 3.5–4.00 | 0.5 | |||
| T1w FRFSE fat sat | ✓ | ✓ | 10.1–19.2 | 400–717 | 3.5–4.00 | 0.5 | |||
MRI and MRCP protocols, including technical details used in Marolf et al., 2011. “Dor” stays for dorsal, “tra” for transverse, “sag” for sagittal, “obl” for oblique, “Min” for minimum, and “Thick” for thickness.
| Marolf et al., 2011, 1.5T GE | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Contrast | Planes | TE ms | TR ms | Thick mm | Gap mm | Matrix | NEX | FOV (cm) | ||||
| Dor | Tra | Sag | Obl | 3D | ||||||||
| T1w fSPGR | ✓ | 3.4 | 160 | 2.0 | 0.2 | 256 × 192 | 1 | 20 | ||||
| T2w FSE fat sat | ✓ | ✓ | ✓ | 68 | 3050 | 3.0 | 0.3 | 256 × 192 | 1 | 18 | ||
| SSFSE | ✓ | 140 | Min | 3.0 | 0 | 256 × 256 | 0.53 | 20 | ||||
| SSFSE fat sat | ✓ | 140 | Min | 3.0 | 0 | 256 × 256 | 0.53 | 20 | ||||
| MRCP FRFSE | ✓ | 250 | 334 | 3.0 | 0 | 256 × 192 | 3 | 24 | ||||
| FAME 3D SPGR | ✓ | Min | 1.0 | 256 × 160 | 1 | 22 | ||||||
|
| ||||||||||||
| FAME 3D SPGR | ✓ | Min | 1.0 | 256 × 160 | 1 | 22 | ||||||
|
| ||||||||||||
| FAME 3D SPGR | ✓ | Min | 1.0 | 256 × 160 | 1 | 22 | ||||||
| MRCP FRFSE | ✓ | 250 | 334 | 3.0 | 0 | 256 × 192 | 3 | 24 | ||||
Figure 1MRI and MRCP proposed protocol for canine and feline patients, including pre-contrast sequence, post-contrast sequences and post-secretin sequence.